Figure 4. Additional Therapies and Proportion Remaining in Remission in Myasthenia Gravis Patients Exposed to Rituximab or Conventional Immunosuppressive Treatment, Respectively.

Number of episodes requiring rescue therapy during the first 24 months after initiating treatment (error bars indicate SD) (A). Proportions of patients (%) in each grade of a global measure of immunotherapies including rituximab after 24 months (B) and frequency treated with low-dose immunosuppressants at 24 months (C). Duration of clinical remission in patients with new-onset disease treated with rituximab or conventional immunotherapy (D).